bronchitis vaccine

✓ Approved

China National Pharmaceutical · 细胞治疗 · 细胞治疗

什么是 bronchitis vaccine？

bronchitis vaccine 是一种细胞治疗，由China National Pharmaceutical研发。该药已获批，用于治疗相关适应症，给药途径：Unknown。

药物档案

公司	China National Pharmaceutical
药物类别	细胞治疗, 疫苗
给药途径	Unknown
状态	Approved

来源： ClinicalTrials.gov, China National Pharmaceutical

治疗适应症

bronchitis vaccine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域	疾病/病症	分期
Respiratory, thoracic and mediastinal disorders	Bronchitis chronic	✓ Approved

相关研究文献

PubMedJournal of virology2026-09-10

Spike protein derived from an apathogenic IBV strain confers attenuated phenotype to a nephropathogenic IBV strain.

Kirk James J, Sives Samantha S, Rayment Adam A, Tappin Amber A et al.

Infectious bronchitis virus (IBV), a Gammacoronavirus, causes the economically damaging disease of poultry, infectious bronchitis. Development of IBV live attenuated vaccines (LAVs) is dependent on the supply of embryonated hens' eggs and attenuation through serial passaging, upwards of 80 times. Vaccine development needs to keep pace with IBV evolution; an issue compounded as cross protection between individual IBV serotypes is unpredictable and often limited. Rational attenuation alongside the ability to propagate LAVs in cell culture offers significant advantages in terms of adaptability, cost, and speed. Most field IBV strains exhibit restricted in vitro tropism, being unable to replicate in primary or continuous cells without serial passage and adaptation. Beaudette, an attenuated IBV strain, is capable of replication in Vero cells, an ability conferred by the spike (S) glycoprotein. In this study, utilizing a recombinant IBV based on the nephropathogenic IBV strain D388, in which the S sequence is replaced with the equivalent sequence derived from Beaudette, we determine that the Beaudette spike can confer the ability to replicate in Vero cells and Beaudette's associated attenuated in vivo phenotype to a distantly related IBV strain. Assessment of infectious progeny and viral RNA in vivo suggests that attenuation was conferred by a tissue tropism-independent molecular mechanism. Analysis of innate immune responses revealed a lower intensity and less inflammatory profile. Our findings support the use of the Beaudette S protein as an avenue for the development of rationally attenuated, cell culture-propagated rIBV vaccines and identify the S protein as a contributor to nephropathogenicity.IMPORTANCEInfectious bronchitis virus (IBV), a Gammacoronavirus of chickens, causes significant economic losses worldwide. Current live attenuated vaccines (LAVs) are generated through extensive serial passage of virulent IBV strains in specific-pathogen-free (SPF) embryonated hen's eggs, upwards of 80 passages. This process is slow, dependent on the availability of SPF embryonated eggs, and the molecular basis of attenuation remains poorly understood. Development of rationally attenuated, cell-culture-based IBV vaccines would enable more rapid responses to emerging viral variants/strains. Using a recombinant IBV, we demonstrated the spike glycoprotein from the attenuated IBV strain Beaudette can confer attenuation and the ability to replicate in Vero cells to a distantly related virulent IBV strain. Attenuation was not linked to changes in tissue tropism but was associated with altered host responses. Our research provides new insights into IBV pathogenesis and presents an avenue for rational attenuation that can be exploited for future development of cell-based IBV vaccines.

PMID 42720295

阅读全文 →

PubMedBiotechnology and bioengineering2026-09-10

Engineering the Vero Cell Lineage: Toward a Programmable Vaccine Manufacturing Platform.

Zhang Hanfu H, Wang Zihao Z, Yang Zhaoqing Z

Vero cells remain an indispensable continuous substrate for human viral vaccine manufacturing. Despite decades of empirical process optimization, intrinsic genomic instability, including segmental aneuploidy and dynamic chromatin rearrangements, continues to limit the durability of engineered phenotypes under sustained viral burden and bioreactor stress. Here, we review the expanding engineering toolkit for the Vero lineage across a three-layered functional framework: the membrane interface, cytoplasmic foundry, and nuclear blueprint, evaluating translational prospects at each level. Receptor transplantation and morphological reprogramming have broadened viral entry range and enabled suspension-adapted culture formats, while metabolic flux management and temporally controlled apoptosis modulation have addressed intracellular production bottlenecks, albeit often with trade-offs between productivity, biosafety, and long-term population stability. At the genomic level, targeted perturbations of transcriptional regulators and emerging epigenetic interventions offer more durable gains, yet expression drift, clonal heterogeneity, and karyotypic instability during extended passaging highlight the need for locus-level precision rather than constitutive trait installation. Looking forward, infection-responsive dynamic logic circuits and the systematic identification of Vero-specific genomic safe harbors could shift the paradigm toward a conditionally responsive manufacturing architecture. Collectively, these advances suggest a pathway for transitioning the Vero lineage from a passive, empirically optimized biological substrate into a conditionally responsive, genomically stable, and programmable platform for modern vaccine preparedness.

PMID 42717571

阅读全文 →

PubMedInnovation (Cambridge (Mass.))2026-09-10

Current landscape and future directions of neoantigen vaccines: A new era of personalized cancer immunotherapy.

Wang Xinyue X, Su Shu S, Tan Siyi S, Chen Xiaosu X et al.

At the forefront of cancer immunotherapy, neoantigens are tumor specific and highly immunogenic, and they have emerged as the key target for personalized oncology. Neoantigen vaccines have demonstrated promising immunologic responses and survival benefit in clinical trials with the combination of chemoradiotherapy and immune checkpoint therapy. This review provides a comprehensive synthesis of biological mechanisms and the next-generation screening approach of cancer neoantigens. We evaluate the current vaccine platforms and the design and vector of cancer neoantigen vaccines, and we additionally analyze strategies to overcome immunosuppressive tumor microenvironment challenges. We conducted a detailed analysis of ongoing and preliminary neoantigen vaccine clinical trials, summarizing existing challenges and areas requiring further improvement. Through an in-depth analysis of the latest research advances, we propose current optimization strategies for neoantigen vaccines, including novel screening models and innovative delivery approaches. Future directions for personalized cancer immunotherapy are outlined, with neoantigen vaccines positioned as pivotal enabling platforms.

PMID 42719780

阅读全文 →

PubMedFrontiers in oral health2026-09-10

Labeled ingredient composition and literature-reported hazard signals in children's toothpastes available through selected UAE retail sources.

Manla Sally S, Al Halabi Manal M, Senok Abiola A, Nassar Rania R et al.

Young children frequently swallow toothpaste during brushing, making the composition of ingredients and the context of exposure relevant to pediatric oral care. To conduct a descriptive survey of children's toothpastes available through selected UAE retail sources and to develop a structured evidence map of literature-reported biological effects associated with labeled ingredients, without performing product-level safety or risk assessment. We surveyed children's toothpastes marketed in the UAE and cataloged labeled ingredients. An evidence-mapping review was conducted to identify published scientific and regulatory reports of biological effects associated with these ingredients. Evidence was classified by source, exposure route, dose relevance, population relevance, evidence consistency, and relevance to routine pediatric toothpaste use. Sixty-five products were identified, including conventionally marketed toothpastes and those labeled as natural, organic, or herbal (NOHT). Both categories contained diverse ingredients, with substantial overlap in excipients such as surfactants, preservatives, humectants, and flavoring agents. Fluoride labeling was more common among conventional products in this sample (a formulation feature and labeling practice, not a safety comparison). Literature-reported biological effects varied widely by ingredient and were derived from regulatory assessments, human studies, animal models, in-vitro experiments, and other exposure contexts, many of which were not directly representative of routine pediatric toothpaste use. In this UAE market sample, conventional and NOHT children's toothpastes shared multiple ingredients for which biological effects have been reported under varying exposure conditions. These findings represent structured hazard identification and evidence mapping rather than quantitative risk assessment. Product-level safety cannot be determined without ingredient concentration and exposure data, and marketing descriptors such as "natural" or "herbal" should not be interpreted as indicators of safety.

PMID 42718570

阅读全文 →

PubMedmBio2026-09-10

Sex and age differences in antibody responses to seasonal influenza vaccination are mediated by estrogenic upregulation of NF-κB and TNF signaling in B cells.

Park Han-Sol H-S, Yin Anna A, Zhou Weiqiang W, Wenstedt Eliane F E EFE et al.

Sex differences in the humoral immune responses to the seasonal quadrivalent influenza vaccine (QIV) in young adults (YA; 18-49 years old) or high-dose QIV in old adults (OA; 75+ years old) were analyzed to determine how age-related changes, including in steroids, impact sex differences in B cells. Among YAs, females had greater H3N2, but not H1N1, neutralizing antibody titers, and greater proportions of hemagglutinin (HA)+ CD19+ B cells and HA+ memory B cells than males through 28 days post-vaccination (DPV), that was not observed among OAs. Machine learning algorithms illustrated that baseline (0 DPV) steroids, including 17-hydroxyprogesterone, estrogens, and testosterone, as well as HA+ CD19+ B cells and HA+ antibody-secreting B cells (ASCs), were major predictors of seroconversion at 28 DPV, particularly in YA. Single-cell RNA sequencing demonstrated that CD19+ B cells from YA females had greater transcriptional activity at 7 DPV than YA males, with upregulation of genes with estrogen-response elements (EREs) along NF-κB-mediated TNF signaling pathways in B-cell subsets, which was mitigated in OA. Estradiol treatment of ASCs from YA females, but not males, increased the number and size of HA+ IgG+ cells and expression of ERE genes along the NF-κB-mediated TNF signaling pathway,that was inhibited by an estrogen receptor antagonist. Pharmacological inhibition of either NF-κB or TNF signaling blocked the ability of E2 to upregulate antibody secretion in cells from YA females. This study provides mechanistic insights into estrogen-mediated increases in influenza vaccine-induced antibody responses among reproductive-aged females and suggests a role for estrogen signaling in the reduction of sex differences in vaccine-induced immunity with old age. Sex differences in influenza vaccine-induced immune responses become less pronounced with old age, which we hypothesize could be related to changes in circulating gonadal steroids. Our study shows that after receipt of the seasonal influenza vaccine, young adult females, who have elevated estrogenic activity, have more B cells that recognize influenza hemagglutinin; their B cells have greater activity along estrogen signaling and inflammatory pathways, and mount stronger antibody responses than young adult males, with these sex differences being mitigated in old adults. We identify estrogen as a key driver of sex differences in influenza immunity by showing that ex vivo estradiol increases antibody production by B cells through the estrogen receptor and engagement with NF-κB. These findings help explain the biological basis for sex differences in vaccine immunity and suggest that the hormonal environment, not just chronological age, shapes how well a person responds to vaccination.

PMID 42720319

阅读全文 →

PubMedNatural product reports2026-09-10

Oxazole- and isoxazole-containing derivatives of high importance in the development of new drugs: natural sources, biogenesis, molecular targets and domino protocols.

Leśniewska Aleksandra A, Przybylski Piotr P

Covering: 2015 to 2026The structural diversity of oxazole- and isoxazole-containing natural products includes both linear and macrocyclic structures. These N,O-heterocycles are produced by a range of organisms, e.g. bacteria, fungi, marine sponges, and plants. The synthesis of oxazoles and isoxazoles via cascade synthetic methods can provide natural product mimics. To better understand the role of the oxazole and isoxazole moieties in drug development from the perspective of the molecular mechanism of action, selected binding modes to molecular targets are discussed and their full list is provided. Although isoxazole- and oxazole-containing natural products are biologically attractive, modifications of their scaffolds are required in many cases to release their full biological potential. The bibliography of the review covers mainly works published in the years from 2015 to 2026.

PMID 42720255

阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

bronchitis vaccine

什么是 bronchitis vaccine？

药物档案

治疗适应症

相关研究文献

Spike protein derived from an apathogenic IBV strain confers attenuated phenotype to a nephropathogenic IBV strain.

Engineering the Vero Cell Lineage: Toward a Programmable Vaccine Manufacturing Platform.

Current landscape and future directions of neoantigen vaccines: A new era of personalized cancer immunotherapy.

Labeled ingredient composition and literature-reported hazard signals in children's toothpastes available through selected UAE retail sources.

Sex and age differences in antibody responses to seasonal influenza vaccination are mediated by estrogenic upregulation of NF-κB and TNF signaling in B cells.

Oxazole- and isoxazole-containing derivatives of high importance in the development of new drugs: natural sources, biogenesis, molecular targets and domino protocols.

了解更多bronchitis vaccine